Emily is a summer student in our Toronto office. She is currently completing her Juris Doctor at the University of Ottawa.
Before pursuing law, Emily completed a Ph.D. in physiology and gained experience working as a scientist genetically modifying pluripotent stem cells for cancer therapy. Following her Ph.D., she worked as a postdoctoral fellow. Her research focus was to generate insulin producing cells for patients living with Type 1 Diabetes.
Emily published five papers and one patent. She was awarded Oral Presentation winner at the University of Toronto’s annual Frontiers in Physiology Conference for her presentation about her thesis topic: Using stem cells for the treatment of Type 1 Diabetes. Emily also won the University of Toronto’s 3 Minute Thesis Competition, People’s Choice Award.
During her legal studies at the University of Ottawa, Emily volunteered as an Assistant Editor of the Ottawa Law Review. She received a Technoship Fellow award from the Law, Technology and Society (CLTS) at the University of Ottawa, where she performed research under the guidance of one of the Faculty of Law professors.
Qualifications
- News
- Speaking
- In the Media
- “Journeys in Commercialization”, guest speaker at a panel, Medicine by Design’s annual commercialization course, University of Toronto, 2024
- 4th year undergraduate course: PSL404 Regenerative Medicine, guest lecturer, University of Toronto, 2021
- Canada First Research Excellence Fund meeting, guest speaker, 2020
Publications
- GP2-enriched pancreatic progenitors give rise to functional beta cells in vivo and eliminate the risk of teratoma formation. Stem Cell Reports. 2022.
- Sufu- and Spop-mediated downregulation of Hedgehog signaling promotes beta cell differentiation through organ-specific niche signals. Nature Communications. 10, 4647, 2019.
- Stem Cells, Self-Renewal, and Lineage Commitment in the Endocrine System. Frontiers in Endocrinology. 10 (2019).
- Efficient Differentiation of Pluripotent Stem Cells to NKX6-1+ Pancreatic Progenitors. J. Vis. Exp. (121), e55265, doi:10.3791/55265, 2017.
- GP2 is a specific cell surface marker of human pancreatic progenitors. Nature Communications. 331, 2017.